23andMe Holding Co logo

23andMe Holding CoNASDAQ: ME

Profile

Sector:

Healthcare

Country:

United States

IPO:

23 November 2020

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$120.14 M
-97%vs. 3y high
46%vs. sector
-vs. 3y high
-vs. sector
-90%vs. 3y high
37%vs. sector
-97%vs. 3y high
16%vs. sector

Price

after hours | Fri, 01 Nov 2024 23:29:38 GMT
$4.65-$0.20(-4.12%)

Dividend

No data over the past 3 years
$40.41 M$54.30 M
$40.41 M-$69.40 M

Analysts recommendations

Institutional Ownership

ME Latest News

23andMe appoints new board members as it works to stem the company's slide
businessinsider.com30 October 2024 Sentiment: NEGATIVE

23andMe said it appointed three new independent directors to its board on Monday. All seven of 23andMe's previous directors resigned in September over its "strategic direction.

23andMe appoints three new board members following abrupt resignations
cnbc.com29 October 2024 Sentiment: NEUTRAL

23andMe appointed three new independent directors to its board, the company said Tuesday. The announcement comes about a month after all seven of 23andMe's previous independent directors abruptly resigned.

23andMe Appoints Three New Independent Directors to Board
globenewswire.com29 October 2024 Sentiment: POSITIVE

SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the “Board”), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In addition, Mr. Jensen has been appointed to serve as the Board's Lead Independent Director.

Avoid This Former High-Flying Stock Split Stock at All Costs
247wallst.com20 October 2024 Sentiment: NEGATIVE

Stock splits are typically viewed as bullish indicators that a company sees more growth is on the horizon.

23andMe Announces Completion of 1-for-20 Reverse Stock Split
globenewswire.com16 October 2024 Sentiment: NEUTRAL

SUNNYVALE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today the completion of the previously announced 1-for-20 reverse stock split of the Company's Class A and Class B common stock and confirmed that such reverse stock split became effective as of 12:01 a.m. EST on October 16, 2024 (the “Effective Time”).

23andMe Announces 1-for-20 Reverse Stock Split
globenewswire.com11 October 2024 Sentiment: NEUTRAL

SUNNYVALE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), announced today that the 1-for-20 reverse stock split of the Company's Class A and Class B common stock will become effective as of 12:01 a.m. EST on October 16, 2024 (the “Effective Time”).

23andMe CEO Wojcicki no longer open to third-party takeover proposals, filing shows
reuters.com30 September 2024 Sentiment: NEUTRAL

Genetic testing firm 23andMe Chief Executive Officer Anne Wojcicki would no longer be open to considering third-party takeover proposals for the company, a regulatory filing showed on Monday.

ME INVESTOR UPDATE: Shareholders of 23andMe Holding Co. are Alerted of Pending Investigation into the Company; Contact BFA Law if You Own Substantial Shares (Nasdaq:ME)
globenewswire.com29 September 2024 Sentiment: NEGATIVE

NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki (“Wojcicki”) of 23andMe breached their fiduciary duties in connection with Wojcicki's ongoing effort to purchase all 23andMe shares she does not already own.

ME INVESTIGATION UPDATE: 23andMe Holding Co. Shareholders are Encouraged to Contact BFA Law about the Potential Lawsuit against the Company
accesswire.com27 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki ("Wojcicki") of 23andMe breached their fiduciary duties in connection with Wojcicki's ongoing effort to purchase all 23andMe shares she does not already own. If you are a holder of 23andMe, you are encouraged to submit your information at: https://www.bfalaw.com/cases-investigations/23andme-holding-co.

ME INVESTOR UPDATE: BFA Law Alerts 23andMe Holding Co. Shareholders to Contact the Firm about its Investigation into the Company's Board of Directors (Nasdaq:ME)
accesswire.com26 September 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki ("Wojcicki") of 23andMe breached their fiduciary duties in connection with Wojcicki's ongoing effort to purchase all 23andMe shares she does not already own. If you are a holder of 23andMe, you are encouraged to submit your information at: https://www.bfalaw.com/cases-investigations/23andme-holding-co.

What type of business is 23andMe Holding Co?

23andMe Holding Co. operates as a consumer genetics testing company in the United States, the United Kingdom, Canada, and internationally. The company operates in two segments, Consumer and Research Services, and Therapeutics. The Consumer and Research Services segment provides personal genome service (PGS) that consists of a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the development of novel therapies; and research and development of programs in various therapeutic areas, such as oncology, immunological and inflammatory diseases, and other disease areas, as well as engages in the out-licensing of intellectual property associated with identified drug targets and expenses related to the discovery and development of therapeutic product candidates. This segment also comprises a therapeutics product portfolio, including 23ME-00610 (P006), a humanized monoclonal antibody that interfere with the ability of CD200R1 to interact with CD200 in cancer cells; GSK6097608, an immuno-oncology program for targeting CD96; and 23ME-01473 is an immuno-oncology antibody program that targets the ULBP6 proteins in the NKG2D pathway. 23andMe Holding Co. was founded in 2006 and is headquartered in South San Francisco, California.

What sector is 23andMe Holding Co in?

23andMe Holding Co is in the Healthcare sector

What industry is 23andMe Holding Co in?

23andMe Holding Co is in the Diagnostics & Research industry

What country is 23andMe Holding Co from?

23andMe Holding Co is headquartered in United States

When did 23andMe Holding Co go public?

23andMe Holding Co initial public offering (IPO) was on 23 November 2020

What is 23andMe Holding Co website?

https://www.23andme.com

Is 23andMe Holding Co in the S&P 500?

No, 23andMe Holding Co is not included in the S&P 500 index

Is 23andMe Holding Co in the NASDAQ 100?

No, 23andMe Holding Co is not included in the NASDAQ 100 index

Is 23andMe Holding Co in the Dow Jones?

No, 23andMe Holding Co is not included in the Dow Jones index

When was 23andMe Holding Co the previous earnings report?

No data

When does 23andMe Holding Co earnings report?

The next expected earnings date for 23andMe Holding Co is 08 November 2024